AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2025)
Historic Free Cash Flow for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$61.5 million.
- AbCellera Biologics' Free Cash Flow fell 2979.87% to -$61.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.1 million, marking a year-over-year increase of 2242.2%. This contributed to the annual value of -$187.0 million for FY2024, which is 5473.08% down from last year.
- Per AbCellera Biologics' latest filing, its Free Cash Flow stood at -$61.5 million for Q3 2025, which was down 2979.87% from -$45.8 million recorded in Q2 2025.
- Over the past 5 years, AbCellera Biologics' Free Cash Flow peaked at $241.7 million during Q2 2022, and registered a low of -$139.3 million during Q3 2022.
- Its 5-year average for Free Cash Flow is -$2.3 million, with a median of -$23.6 million in 2024.
- Data for AbCellera Biologics' Free Cash Flow shows a peak YoY increase of 796198.96% (in 2021) and a maximum YoY decrease of 1157053.57% (in 2021) over the last 5 years.
- Over the past 5 years, AbCellera Biologics' Free Cash Flow (Quarter) stood at -$26.1 million in 2021, then soared by 171.08% to $18.6 million in 2022, then crashed by 283.2% to -$34.0 million in 2023, then surged by 30.59% to -$23.6 million in 2024, then plummeted by 160.36% to -$61.5 million in 2025.
- Its Free Cash Flow stands at -$61.5 million for Q3 2025, versus -$45.8 million for Q2 2025 and -$22.2 million for Q1 2025.